Wegovy vs. Zepbound
Wegovy and Zepbound target different needs within weight management. Wegovy is a GLP-1 receptor agonist offering substantial weight loss (15% of bodyweight), while Zepbound is a dual GIP and GLP-1 agonist. The GIP agonist component enhances the effect of both incretin hormones and also improves insulin sensitivity and fat metabolism. Zepbound offers average weight loss of up to 21% of bodyweight, while Wegovy offers average weight loss of 15% of bodyweight. Both drugs are approved for chronic weight management and do not have notable off-label uses. Side effects like nausea and vomiting are consistent between them, as are serious risks such as pancreatitis. Wegovy's cost averages $1,375/month, while Zepbound's cost is unavailable in the data. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions